Vol.145 Weekly Report on Investment and Financing of Medical Health

Beixin completed hundreds of millions of yuan in Series C financing and built a world-class innovative platform for active interventional medical devices.

On December 31, 2020, it was learned that Shenzhen Beixin Life Science and Technology Co., Ltd. recently completed hundreds of millions of RMB Series C financing. This round of financing was led by Qiming Venture Capital, and the old shareholders SDIC Chuanghe, sequoia capital china and Taiyu Investment continued to be blessed, with Dianshi Capital as the exclusive financial advisor. The funds raised in this round will be used for the company to further accelerate marketing, consolidate R&D strength and open up new product lines. Beixin is a national high-tech enterprise, which is committed to building a high-performance platform for active intervention in medical device technology innovation, developing into a leading enterprise in the field and a world-class medical technology enterprise with long-term influence. The company has provided leading-edge overall solutions around the precise interventional diagnosis and treatment of coronary heart disease, and is expanding into the field of peripheral blood vessels and cardiac rhythm. Beixin will continue to provide "China Zhizao" high-performance innovative medical device products and professional services to doctors and patients all over the world.

　

Keruichi Medical has completed several hundred million yuan of Series C financing for clinical promotion of tumor interventional products.

On December 30, 2020, it was learned that Keruichi Medical, an innovative platform for vascular intervention in China, recently announced the completion of the C-round financing of several hundred million yuan, which was jointly led by Gaoying Venture Capital and Yuansheng Venture Capital. This round of financing funds is mainly used for clinical promotion of tumor interventional products, registration of multiple products under research, research and development of follow-up pipeline projects, brand marketing and channel construction.

　

Maidi Peak received more than RMB 1 billion in Series C financing for upgrading the production line.

On December 31, 2020, Beijing Maidi Dingfeng Medical Technology Co., Ltd. announced that it had obtained more than RMB 1 billion in Series C financing. This round was jointly led by Qingsong Capital and Lanxin Asia, followed by Yingrui Capital, Yuexiu Industrial Fund and Weijing Capital. Sanjiang Capital is the exclusive financial advisor for this round of financing. This transaction is one of the largest cases in the field of medical devices this year. This round of financing will be mainly used for upgrading the production line, intensifying R&D, speeding up the clinical trial and registration of products, expanding the sales network and improving the commercial promotion, so as to better serve the patients’ demand for high-quality medical equipment and high-end consumables. Maidi Peak is an innovative high-tech enterprise that develops high-quality medical equipment and high-end consumables around cardiovascular diseases and provides overall medical solutions.

　

Yixin Medical completed $70 million Series B financing to promote the development of mitral valve interventional replacement products.

On December 30, 2020, Yixin Medical Group, a cardiovascular innovative medical device enterprise, completed the series B financing with a total amount of 70 million US dollars. This round of financing was led by Dacheng Capital, led by CICC Kai Tak Fund and related funds under CICC Capital, and followed by CITIC Securities and Tonghe Yucheng. This round of financing will be used for clinical trials, registration and market access of the company’s world-leading interventional mitral valve products and coronary balloon products, and for preclinical research of other products under research in the pipeline.

　

Minolta Micro-invasive has completed 10 million rounds of pre-A financing for the research and development of its cerebrovascular stent and embolectomy device.

On December 30, 2020, it was learned that Mino Micro-Innovation had completed 10 million pre-A rounds of financing. This round of financing is invested by Shanghai Chuangrui Investment Co., Ltd., and the funds raised will be mainly used for the research and development of its cerebrovascular stent and embolectomy device. Meinuo minimally invasive is an innovative medical device research and development enterprise focusing on the field of minimally invasive intervention of cerebrovascular diseases. Its products cover micro-guide wires, micro-catheters, spring coils, balloon catheters, stents and embolizers. The company has completed the core research and development of six products in the field of hemorrhagic stroke and ischemic stroke in the United States, and obtained five product patents, among which micro-guide wire and micro-catheter have accepted the medical device certification, and it is expected that they can get the registration certificate and start selling in February-March 2021.

　

Yingzi Medical completed nearly 100 million yuan of Series B financing, which was led by Sequoia Capital.

On December 29, 2020, it was learned that recently, Yingzi Medical Technology (Hangzhou) Co., Ltd. (hereinafter referred to as "Yingzi Medical"), a professional platform enterprise for medical devices, announced that it had completed nearly 100 million yuan of Series B financing, which was led by Sequoia Capital and followed by the original shareholder Stowe Capital. The funds raised in this round will be used to further strengthen R&D strength, business development, medical education, marketing promotion and talent development. It is reported that Yingzi Medical will launch the first batch of innovative gynecological medical device product portfolio in 2021, and launch a national-level clinical medical education and training program with gynecological minimally invasive surgery as the core.

　

Tengfu Medical completed tens of millions of angel round financing to promote the clinical research of pulmonary thrombotic clearance system.

On December 29, 2002, it was learned that Shenzhen Tengfu Medical Technology Co., Ltd. (hereinafter referred to as "Tengfu Medical"), a medical device research and development company for interventional treatment of pulmonary embolism, recently completed tens of millions of angel round financing, which was invested by Hechuang Capital. This round of financing is mainly used to promote the clinical research work of the company’s pulmonary thrombosis clearance system. The core members of Tengfu Medical are composed of members who have been engaged in the research and development of interventional devices for more than 10 years. Now they focus on the research and development, production and sales of interventional medical devices for pulmonary embolism, and are committed to filling the gap in the field of interventional surgical treatment of pulmonary embolism in China.

　

Sino-VIA completed the 200 million yuan D round of financing, and the domestic CT giant extended from imaging to diagnosis and treatment.

On December 31, 2020, Sino-VIA Technology (Beijing) Co., Ltd. announced that it had obtained a series D financing of RMB 200 million, which was jointly led by Yangzhou Longtou Houde Emerging Industry Investment Partnership (Limited Partnership) and Shenzhen Venture Capital. The funds raised this time will be used to increase investment in CT image research and development and key technology research, and further accelerate the deployment of 5G+ robot navigation products in medical institutions at all levels; Promote the multidisciplinary development of medical imaging from diagnosis to treatment; Accelerate the application of artificial intelligence images in the construction of smart medical care and internet medical care. Sano VIA is a high-end X-ray medical imaging equipment supplier, providing products and services including X-ray computed tomography device, sROBOT CT navigation system and sAI intelligent imaging solution.

　

Noel Medical completed 30 million Pre-A rounds of financing to promote Noel’s first clinical trial of 3.0T magnetic resonance compatible SEEG electrode in the world.

On December 29th, 2020, Noel Medical announced the completion of 30 million Pre-A round of financing, which was jointly invested by Aussie Capital and Yuansheng Venture Capital, and the old shareholders followed suit. Yang Huan, founder of Noel Medical, said that after this round of financing, Noel Medical will accelerate the clinical trial of Noel’s first 3.0T magnetic resonance compatible SEEG electrode, product registration and the research and development layout of subsequent software and hardware products, and simultaneously promote the construction of intelligent AI-aided diagnosis data platform based on the core algorithm of SEEG technology. In the future, Noel will continue to make use of the built brain big data platform, combined with multi-product pipeline intelligent software and hardware products, and continue to promote the in-depth layout of brain science and function in many fields.

　

Manteia, an intelligent radiotherapy company, completed a series of financing of 100 million yuan, which was jointly invested by Danlu Capital and Deyi Capital.

On December 28th, 2020, Manteia Technology, a research and development company of adaptive radiotherapy system, completed a round of financing of 100 million yuan, which was jointly invested by Danlu Capital and Deyi Capital, well-known institutions in the medical field. The three parties will unite various resources to make Manteia gain greater advantages in the future global competition pattern of radiotherapy products. Manteia products are mainly adaptive radiotherapy treatment system and commonly used radiotherapy product modules, algorithm component libraries and plug-ins. Provide more efficient and accurate intelligent planning tools (automatic drawing, automatic planning, biological optimization, etc.) and systems for clinical treatment.